Leerink Swann Starts Optimer Pharmaceuticals (OPTR) at Outperform
Tweet Send to a FriendGet Alerts OPTR Hot Sheet
Price: $14.48 -1.3%
Rating Summary:
5 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade OPTR Now!
Leerink Swann initiated coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Outperform rating and price target of $25.00.
Analysts think Optimer Pharmaceuticals represents a solid near- and long-term biotech pick for based on potential of approved drug DIFICID (fidaxomicin).
“Near-term sales growth is likely to be driven by maturing DIFICID hospital formulary access, implementation of CMS’s New Technology Add-on Payment (NTAP) reimbursement program, and increasing use in Long- Term Care facilities (LTCs),” said analyst Marko Kozul.
“Longer term, sNDA approval of DIFICID for special immune-compromised populations such as those undergoing Bone Marrow Transplants (BMT) should provide another key revenue driving inflection point,” he added.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $14.49 yesterday, with a 52 week range of $10.00-$17.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analysts think Optimer Pharmaceuticals represents a solid near- and long-term biotech pick for based on potential of approved drug DIFICID (fidaxomicin).
“Near-term sales growth is likely to be driven by maturing DIFICID hospital formulary access, implementation of CMS’s New Technology Add-on Payment (NTAP) reimbursement program, and increasing use in Long- Term Care facilities (LTCs),” said analyst Marko Kozul.
“Longer term, sNDA approval of DIFICID for special immune-compromised populations such as those undergoing Bone Marrow Transplants (BMT) should provide another key revenue driving inflection point,” he added.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $14.49 yesterday, with a 52 week range of $10.00-$17.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst
- Topeka Capital Starts Cavium Networks (CAVM) at Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
